5-Aminomethyl-4-chlorothiophene-3-thiocarboxamide | 742045-65-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-Aminomethyl-4-chlorothiophene-3-thiocarboxamide
• 英文别名: 5-(Aminomethyl)-4-chlorothiophene-3-carbothioamide
• CAS: 742045-65-4
• 化学式: C₆H₇ClN₂S₂
• 分子量: 206.72
• InChiKey: JCQLHILYDSQNTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Aminomethyl-4-chlorothiophene-3-thiocarboxamide 、 (S)-1-[(R)-2-(tert-Butoxycarbonyl-tert-butoxycarbonylmethyl-amino)-3-cyclohexyl-propionyl]-2,5-dihydro-1H-pyrrole-2-carboxylic acid 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Orally active thrombin inhibitors. Part 1: Optimization of the P1-moiety

  摘要：

  The synthesis and SAR of novel nanomolar thrombin inhibitors with the common backbone HOOC-CH2-D-cyclohexylalanyl-3,.4-dehydroprolyl-NH-CH2-aryl-C(=NH)NH2 are described together with their ecarin clotting time (ECT) prolongation as measure for thrombin inhibition ex vivo. The aryl P1-moiety mimicking the arginine part of the D-Phe-Pro-Arg derived thrombin inhibitors turned out to be a key component for in vitro potency and in vivo activity. Optimization of this part led to compounds with improved antithrombin activity in rats and dogs after oral administration compared to the recently launched anticoagulant melagatran. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.02.040
• 作为产物：
  描述：

  2-氨基-4-氯-3-氰基-5-甲酰基噻吩 在 亚硝酸特丁酯 作用下， 以 N-甲基乙酰胺 、 乙腈 为溶剂， 生成 5-Aminomethyl-4-chlorothiophene-3-thiocarboxamide
  参考文献：
  名称：

  Low molecular weight inhibitors of complement proteases

  摘要：

  本文描述了肽物质、其制备和其作为补体抑制剂的用途。这些物质特别是具有鸟氨酸或酰胺基团作为末端基团的物质。特别地，本文描述了抑制补体蛋白酶C1s和C1r的抑制剂。

  公开号：

  US06683055B1

文献信息

• Low-molecular serine proteases inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals
  申请人：——

  公开号：US20040048815A1

  公开（公告）日：2004-03-11

  The invention relates to novel amidines and quanidines, the production and use thereof and the use thereof as trypsine-type serine protease competitive inhibitors, especially thrombine and compliment proteases CIs and C1r. The invention also relates to pharmaceutical compositions which contain said compounds as active ingredients, in addition to the use of the compounds as thrombine inhibitors, anticoagulants, compliment inhibitors and anti-inflammatory agents. The novel compositions are characterised by the linkage of a serine protease inhibitor having amidine or quanidine functions with an alkyl radical having two or more hydroxyl functions, whereby said alkyl radical is derived from sugar derivates.Several sugar structural components or components derived from sugar can therefore be linked to each other. Said principle of linking sugar derivates enables oral active compounds to be obtained.

  本发明涉及新型的氨基脲和胍类化合物，其生产和使用以及作为胰蛋白酶类丝氨酸蛋白酶竞争性抑制剂的用途，特别是作为凝血酶和补体蛋白酶CIs和C1r的抑制剂。本发明还涉及含有所述化合物作为活性成分的制药组合物，以及将该化合物用作凝血酶抑制剂、抗凝剂、补体抑制剂和抗炎剂的用途。新型组合物的特点是将具有氨基脲或胍类功能的丝氨酸蛋白酶抑制剂与具有两个或更多羟基功能的烷基基团连接起来，所述烷基基团源自糖衍生物。因此，几种糖结构组分或从糖中衍生的组分可以相互连接。这种将糖衍生物连接起来的原理使得可以获得口服活性化合物。
• LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS
  申请人：Herr Dieter

  公开号：US20110071285A1

  公开（公告）日：2011-03-24

  The invention relates to novel amidines and quanidines, the production and use thereof and the use thereof as trypsine-type serine protease competitive inhibitors, especially thrombine and compliment proteases CIs and C1r. The invention also relates to pharmaceutical compositions which contain said compounds as active ingredients, in addition to the use of the compounds as thrombine inhibitors, anticoagulants, compliment inhibitors and anti-inflammatory agents. The novel compositions are characterised by the linkage of a serine protease inhibitor having amidine or guanidine functions with an alkyl radical having two or more hydroxyl functions, whereby said alkyl radical is derived from sugar derivates. Several sugar structural components or components derived from sugar can therefore be linked to each other. Said principle of linking sugar derivates enables oral active compounds to be obtained.

  本发明涉及新型的酰胺和脲类化合物，其生产和使用以及作为胰蛋白酶型丝氨酸蛋白酶竞争性抑制剂的用途，特别是作为凝血酶和补体蛋白酶CIs和C1r的抑制剂。本发明还涉及含有该化合物作为活性成分的制药组合物，以及将该化合物用作凝血酶抑制剂、抗凝剂、补体抑制剂和抗炎药的用途。这些新型化合物的特点是将具有酰胺或脲基功能的丝氨酸蛋白酶抑制剂与具有两个或更多羟基功能的烷基基团连接起来，其中该烷基基团来源于糖衍生物。因此，几种糖结构组分或从糖中衍生的组分可以相互连接。该连接糖衍生物的原理使得可以获得口服活性化合物。
• [DE] THROMBININHIBITOREN<br/>[EN] THROMBIN INHIBITORS<br/>[FR] INHIBITEURS DE LA THROMBINE
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：WO1999037668A1

  公开（公告）日：1999-07-29

  (DE) Es werden Verbindungen der Formel A-B-D-E-F, worin A, B, D, E und F die in der Beschreibung angegebene Bedeutung besitzen, und deren Herstellung beschrieben. Die neuen Verbindungen eignen sich zur Herstellung von Medikamenten.(EN) The invention relates to compounds of the formula A-B-D-E-F, in which A, B, D, E and F have the meanings given in the description, and to their production. These new compounds are suitable for producing medicines.(FR) L'invention concerne des composés de formule A-B-D-E-F, dans laquelle A, B, D, E et F ont la signification mentionnée dans la description, ainsi que leur procédé de fabrication. Ces nouveaux composés sont utiles pour la préparation de médicaments.

  这种化合物涉及分子式为 A-B-D-E-F 的结构，其中 A、B、D、E 和 F 的含义在说明中给出，以及它们的生产过程。这些新的化合物可用于 制药。
• THROMBININHIBITOREN
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP1051431A1

  公开（公告）日：2000-11-15
• NIEDERMOLEKULARE INHIBITOREN VON KOMPLEMENTPROTEASEN
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP1169338A2

  公开（公告）日：2002-01-09